Tags : Therapeutics MD


Theramex Signs an Exclusive License Agreement with Therapeutics MD to

Shots: Therapeutics MD to receive $15.82M upfront, $33.34M milestones including $2.26M as regulatory milestones & $31.08M as commercial milestones and royalties on sales in licensed territories Theramex to get exclusive commercialization rights for Bijuva and Imvexxy outside the US and is responsible for all regulatory and commercial activities in the licensed territories. Additionally, Therapeutics MD […]Read More


Therapeutics MD’s Annovera (Segesterone Acetate/Ethinyl Estradiol) Receives FDA Approval for

Shots: The approval is based on 17 clinical trials results assessing Annovera in 2,308 women aged ≤35yrs The study demonstrated in prevention of 97.3% pregnancy, Pearl Index (PI) 2.98/100 women with overall satisfaction rate is 89% Annovera is a combination of estrogen (ethinyl estradiol, 0.15 mg/day) & Nestorone (segesterone acetate,0.013 mg/day) used for prevention of ovulation […]Read More